Surgical de-escalation strategies for non-small cell lung cancer following neoadjuvant chemoimmunotherapy: a propensity score-matched analysis
In brief
De-escalated lung surgery lowered complications but was linked to fivefold local recurrence
In a two-center retrospective study of 166 patients with central lung cancer treated with chemoimmunotherapy, less extensive surgery was associated with fewer complications and less postoperative breathlessness. After matching, survival outcomes were similar, but local recurrence was about five times more likely. The findings support careful patient selection and close surveillance, but need confirmation in larger studies.
- Journal
- Translational lung cancer research (Q1)
- Published
- 29 September 2026
- Study design
- Retrospective cohort
- Evidence level
- Level 3, Low (CEBM 3b)
- Authors
- Yulong Wang, Bengang Hui, Xin Wang, Guihu Lin, Xun Wang, Xiao Li
- PMID
- 42999650
- DOI
- 10.21037/tlcr-2026-0911
Why clinicians should know about it
- Picked for Surgical Oncology (paper of the day, 10 November 2026): Directly evaluates surgical de-escalation after neoadjuvant chemoimmunotherapy
Abstract
BACKGROUND: Surgical de-escalation holds promise for non-small cell lung cancer (NSCLC) following neoadjuvant chemoimmunotherapy (NACI), but evidence remains scarce. We aimed to assess the safety and clinical outcomes of surgical de-escalation following NACI in central NSCLC. METHODS: A dual-center retrospective cohort study included 166 patients with locally advanced central NSCLC who received NACI followed by curative surgical resection. Patients were stratified into modified (surgical de-escalation) and unmodified groups. Propensity score matching (PSM) was performed to balance baseline covariates, with standardized mean difference ≤0.1 indicating optimal balance. Primary endpoint comprised event-free survival (EFS), and Secondary endpoints included overall survival (OS), recurrence-free survival (RFS), local recurrence-free survival (LRFS), and health-related quality of life (HRQoL). Survival outcomes were analyzed using the Kaplan-Meier method and Cox proportional hazards regression to estimate hazard ratios (HR) and confidence intervals (CIs). RESULTS: At a median follow-up of 33.9 months, the modified surgery group showed superior 3-year EFS (75.2% vs. 63.4%, HR =0.56, P=0.04) and RFS (73.6% vs. 64.3%, HR =0.51, P=0.03) in the unmatched cohort. After PSM, EFS, RFS, and OS were comparable (all P>0.05); nevertheless, the modified surgery group demonstrated a significantly higher risk of local recurrence (HR =5.39, 95% CI: 1.18-24.61, P=0.03). The incidences of perioperative complications and postoperative dyspnea were consistently lower in the modified group before and after PSM (all P<0.05). CONCLUSIONS: For carefully selected central NSCLC patients, surgical de-escalation following NACI was associated with lower postoperative dyspnea scores and yielded comparable oncological outcomes. Rigorous surveillance is warranted due to the heightened risk of local recurrence.
Abstract as published, via PubMed.
For healthcare professionals. The summary is generated by AI from the published abstract, and the evidence level is assigned automatically from the study design on the Oxford CEBM hierarchy. Neither is medical advice. Read the full paper before changing practice.